letter to shareholders 2005

Final paragraph from Chairman Jones
"CBIO is the real thing. The board is confident that in the next few months we will settle on a term sheet with a multinational... We believe that a sale value of at least $2 billion could be achieved. We anticipate that the company will not be in the hands of current shareholders by the end of the year..."
Letter to shareholders Dec 2007 from Jones " the company is about to start it's Phase 2(a) 150 person placebo controlled 3 arm clinical trial in RA patients. This trial will not complete before the end of 2008" TOO RIGHT, JUST SNUCK IN BEFORE THE END OF 2011!
Fortunately, the drug will prevail over inept, inexperienced management. In Jones speak (address to shareholders Nov 16, 2005) " the clinician conducting this study (RA)is astonished with the results in RA, these results are compelling and beyond contestation."